

Quantitating Ventricular Function With Echocardiography: How do you use LV Strain in Daily Practice? Miguel A. Quinones, MD, MACC, FASE Houston Methodist DeBakey Heart & Vascular Center

Disclosures: nothing to disclose



Evaluation of LV Function



- Represents ~60-80% of clinical indication for an echocardiogram
- For 5 decades EF has been the main parameter of systolic LV function

EF = (EDV - ESV) / EDV

Assessment of LV function: limitations of Ejection Fraction



- Measurement (or estimate) variability with TTE
 - Best with CMR
- Influenced directly by preload and inversely by afterload
- It is a measure of pump function rather than myocardial function
 - A variety of heart conditions with preserved EF have been shown to have myocardial dysfunction and poor outcomes (EX: HFpEF, chronic MR)
- Variable outcomes seen in the range between 35 and 50%



Myocardial Deformation by 2D-Speckle Tracking: Strain Imaging



An attempt to assess myocardial function separate from pump function



(Arrow length proportional to deformation)



Strain = $\Delta L/Lo$ Strain rate = ($\Delta L/Lo$)/t

Ventricular Mechanics Helix and Loops and Mechanical Activation







Manel Ballester-Rodés, Spain and Jagat Narula, Irvine

Myocardial Deformation/Strain by Speckle Trackinga

Delgado V, et al. JACC 2008

Radial Strain

-a measurement of segmental myocardial thickening

Circumferential Strain

-a measurement of segmental myocardial circumferential shortening

Longitudinal Strain

-a measurement of segmental myocardial longitudinal shortening





Speckle Tracking - Strain





Speckle Tracking - Strain





FULL TEXT ARTICLE Normal Global Longitudinal Strain a 🔊 🔁



<u>% CI</u>

25.00

Nicholas D'Elia BMSci (Hons) MBBS, GDip, Stefano Caselli MD, PhD, Wojciech Kosmala MD, PhD, Patrizio Lancellotti MD, PhD, Daniel Morris MD, Denisa Muraru MD, PhD, Masaaki Takeuchi MD, PhD, Annemien van den Bosch MD, PhD, Roderick W.J. van Grootel MS, Hector Villarraga MD and Thomas H. Marwick MBBS, PhD, MPH JACC: Cardiovascular Imaging, 2020-01-01, Volume 13, Issue 1, Pages 167-169, Copyright © 2020 American College of Cardiology Foundation Normal values for Average Peak GLS: variation by vendors (n = 2396)

The **normal range for GLS varied between the vendors**, with **TomTec** presenting the **highest** values (n = 644; 22.1% [20.1, 23.8], LLN 18.0%), **followed by GE** (n = 1,013; 21.%2 [19.9, 22.8], LLN 18.2%), **Toshiba** (n = 278; 19.9% [18.3, 21.5], LLN 15.8%), **Philips** (n = 379; 19.6% [18.1, 21.3], LLN 15.5%), and **Siemens** (n = 82; 16.9% [16.0, 18.8], LLN 14.0%), differences being statistically significant (1-way analysis of variance p < 0.01). **Regardless of vendor or clinical covariate, a GLS <16% likely indicates significant myocardial dysfunction.**



| | | ~ | | | | | | |
|-----------|--------|-------|-------|--------|--------|------|-------|---|
| Kockabay | 21.500 | 0.127 | 0.016 | 21.251 | 21.749 | | 1 | |
| Moris | 21.230 | 0.113 | 0.013 | 21.009 | 21.451 | | | |
| Caselli | 19.400 | 0.325 | 0.106 | 18.762 | 20.038 | | | |
| Charfeddi | 22.990 | 0.519 | 0.269 | 21.973 | 24.007 | | | |
| Cheng | 22.000 | 0.147 | 0.022 | 21.712 | 22.288 | | | |
| Cheng | 20.200 | 0.166 | 0.028 | 19.874 | 20.526 | | 1.1 | |
| Cong | 20.340 | 0.542 | 0.294 | 19.277 | 21.403 | | | - |
| Eun | 17.300 | 0.539 | 0.290 | 16.245 | 18.355 | | ÷ . | |
| Menting | 20.800 | 0.161 | 0.026 | 20.485 | 21.115 | | | 1 |
| Sugimoto | 22.500 | 0.115 | 0.013 | 22.274 | 22.726 | | | |
| Kotwica | 22.000 | 0.372 | 0.138 | 21.271 | 22.729 | | | |
| | 20.166 | 0.348 | 0.121 | 19.484 | 20.848 | | | - |
| | | | | | | | | |
| | | | | | | 0.00 | 12 50 | |
| | | | | | | | | |

27

Potential Applications of Peak Average GLS in Routine Clinical Practice



- Detection of subclinical LV dysfunction in a variety of diseases
- Objective assessment of global and regional function
- Regional patterns associated with myocardial diseases
- Better prediction of serious CV outcomes
 - lower values (without the sign), worse prognosis



45M with severe hypertension and ESRF





LVEF > 75%; Cavity Obliteration

45M with severe hypertension and ESRF





Current studies in progress looking at GLS outcome prediction in patients with ESRF

Potential Applications of Peak Average Global Longitudinal Strain

DEBAKEY HEART & VASCULAR CENTER

- Detection of subclinical LV dysfunction
 - hypertension
 - HCM
 - diabetes
 - acute transplant rejection
 - Valvular lesions: MR, AR, AS
 - Sepsis
 - HFpEF
- The list is growing

Use of Strain Imaging for regional function

Concordance with the eye: multiple WMAs







Use of Strain Imaging to Detect RWMAs







Use of Strain Imaging to Detect RWMAs





54 F with a ? Hx of an old MI



HOUSTON

54 F with a ? Hx of an old MI



Inferior

HOUSTON

Methodist

DEBAKEY HEART & VASCULAR CENTER

54 F with a ? Hx of an old MI



Contrast Given



4C

Regional Patterns in Myocardial Diseases



Normal coronary angio ٠



HOUSTON



κ Light Chain 135 mg/L [3.3 – 19.4 ng/mL] λ Light Chain 63.8 mg/L [5.7 – 26.3 mg/L] κ / λ2.11 [0.26 – 1.65] Acute presentation of cardiac light chain amyloidosis

79F with recent chest pain





79F with recent chest pain



CMR

Contrast Echo



DX: Apical HCM

Potential Applications of Peak Average GLS in Routine Clinical Practice



- Detection of subclinical LV dysfunction in a variety of diseases
- Objective assessment of global and regional function
- Regional patterns associated with myocardial diseases
- Better prediction of serious CV outcomes
 - lower values (without the sign), worse prognosis



Early Detection and Prediction of Cardiotoxicity in Chemotherapy

Journal of the American College of Cardiology © 2014 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 63, No. 25, 2014 ISSN 0735-1097/\$36.00 http://dx.doi.org/10.1016/j.jacc.2014.01.073

VASCULAR CENTER

HOUSTON

STATE-OF-THE-ART PAPERS

ASE/EACVImaging consensus document (*Plana, JC, JASE 2014*) recommendations:

a relative change in GLS less than 8% is not meaningful, whereas a change greater than 15% is likely to indicate subclinical LV dysfunction

Paaladinesh Thavendiranathan, MD,*† Frédéric Poulin, MD,* Ki-Dong Lim, MD,* Juan Carlos Plana, MD,‡ Anna Woo, MD,* Thomas H. Marwick, MD§

Toronto, Ontario, Canada; Cleveland, Ohio; and Hobart, Australia

A 10-15% reduction on Pk Avrg GLS appears to be the most useful parameter for prediction of a >5% fall in EF during chemotherapy

Value of GLS in Predicting Cancer Therapy Related Cardiac Dysfunction (>5% EF drop)



- Meta-analysis (Oikonomou E, et.al. JAMA cardiol Aug 2019)
 - a ≥10-15% drop in GLS with chemotherapy had varying sensitivity and specificity for CTRCD
 - absolute GLS values during treatment also have comparable prognostic value for detecting CTRCD
 - The threshold active treatment absolute GLS value to identify risk has been variable in the literature, with most studies suggesting a value between 18.0% and 19.0% (median, 18.0%)
 - Baseline GLS may also flag patients at risk of CTRCD, possibly through detection of preexisting subclinical dysfunction, which may be aggravated by chemotherapy

More studies are needed

Global Longitudinal Strain to Predict Mortality in Patients With Acute Heart Failure (HRpEF and HFrEF Combined)



Jin Joo Park, MD, PHD,^a Jun-Bean Park, MD, PHD,^b Jae-Hyeong Park, MD, PHD,^c Goo-Yeong Cho, MD, PHD^a

JACC 71: 2018

N=4312



5-year All-cause Mortality

ORIGINAL RESEARCH

Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients



March 2022

ΙΟυςτοΝ

Anne G. Raafs, MD 🝺 †; Andrea Boscutti, MD †; Michiel T. H. M. Henkens, MD 🝺; Wout W. A.

A total of 323 patients with DCM (66% men, age 55±14 years) under optimal Rx for HF were included.



Number at risk

- LVEF >40% and GLS better than -13%
- --- LVEF >40% and GLS worse than -13%
- LVEF <40% and GLS better than -13%</p>
- --- LVEF <40% and GLS worse than -13%

Association of Left Ventricular Global Longitudinal Strain With Asymptomatic Severe Aortic Stenosis Natural Course and Prognostic Value

E. Mara Vollema, MD; Tadafumi Sugimoto, MD; Mylène Shen, MSc; Lionel Tastet, MSc, MS; Arnold C. T. Ng, MD, PhD; Rachid Abou, MD; Nina Ajmone Marsan, MD, PhD; Bart Mertens, PhD; Raluca Dulgheru, MD; Patrizio Lancellotti, MD, PhD; Marie-Annick Clavel, DVM, PhD; Philippe Pibarot, DVM, PhD; Philippe Genereux, MD; Martin B. Leon, MD; Victoria Delgado, MD, PhD; Jeroen J. Bax, MD, PhD

Development and Intervention in Patients With Asymptomatic Aortic Stenosis

Symptoms development



Action Methodist DEBAKEY HEART & VASCULAR CENTER

Intervention



FULL TEXT ARTICLE Left Ventricular Global Longitudinal Strain in Patients with Moderate Aortic Stenosis S



| Number at risk | isk | | | | | | | |
|---------------------------|-----|-----|-----|-----|-----|-----|----|--|
| LVEF ≥50% and LV GLS <16% | 156 | 143 | 115 | 95 | 72 | 56 | 49 | |
| LVEF ≥50% and LV GLS ≥16% | 229 | 222 | 189 | 156 | 134 | 112 | 93 | |

FULL TEXT ARTICLE Left Ventricular Global Longitudinal Strain in Patients with Moderate Aortic Stenosis



Jan Stassen MD, Stephan M. Pio MD, See Hooi Ewe MD, PhD, Gurpreet K. Singh MD, Kensuke Hirasawa MD, PhD, Steele C. Butcher MD, MPhil, David J. Cohen MD, MSc, Philippe Généreux MD, PhD, Martin B. Leon MD, PhD, Nina Ajmone Marsan MD, PhD, Victoria Delgado MD, PhD and Jeroen J. Bax MD, PhD Journal of the American Society of Echocardiography, 2022-08-01, Volume 35, Issue 8, Pages 791-800.e4, Copyright © 2022 American

Society of Echocardiography



Strain Echocardiography and Functional Capacity in Asymptomatic Primary Mitral Regurgitation With Preserved Ejection Fraction

Amgad Mentias, MD, Peyman Tomislav Mihaljevic, MD, Rak Richard A. Grimm, DO, Brian



HOUSTON

JACC 2016

ASCULAR CENTER

FULL TEXT ARTICLE

Myocardial Strain in Prediction of Outcomes After Surgery for Severe Mitral Regurgitation S

Hyue Mee Kim MD, Goo-Yeong Cho MD, PhD, In-Chang Hwang MD, Hong-Mi Choi MD, Jun-Bean Park MD, PhD,

Yeonyee E. Yoon MD and Hyung-Kwan Kim MD, PhD

JACC: Cardiovascular Imaging, 2018-09-01, Volume 11, Issue 9, Pages 1235-1244, Copyright © 2018 American College of Cardiology Foundation



Myocardial Strain in Prediction of Outcomes After Surgery

Hyue Mee Kim MD, Goo-Yeong Cho MD, PhD, In-Chang Hwang MD, Hong-Mi Choi MD, Jun-Bean Park MD, PhD,

Yeonyee E. Yoon MD and Hyung-Kwan Kim MD, PhD

JACC: Cardiovascular Imaging, 2018-09-01, Volume 11, Issue 9, Pages 1235-1244, Copyright © 2018 American College of Cardiology Foundation



Risk-Adjusted Event-Free Survival According to GLS Event-free survival curves are shown according to the GLS (-18.1%), adjusted for significant univariate predictors. (A) Event-free survival curve for cardiac events. (B) Event-free survival curve for all-cause death. <u>J Intensive Care.</u> 2022; 10: 29. Published online 2022 Jun 15. doi: <u>10.1186/s40560-022-00621-8</u> PMCID: PMC9199206

PMID: 35706065



Construction of a predictive model and prognosis of left ventricular systolic dysfunction in patients with sepsis based on the diagnosis using left ventricular global longitudinal strain



Quantitating Ventricular Function: How to use Global Longitudinal Strain?

Limitations of Strain Imaging

- Quality of image alters accuracy
 - contrast cannot be used



Figure 1 GLS Learning curve. ICC of each group compared with expert over consecutive quartiles of 25 cases.

Chang J, JASE Nov 2017



Quantitating Ventricular Function: How to use Global Longitudinal Strain?



Limitations of Strain Imaging

- Quality of image alters accuracy
 - contrast cannot be used
- Strain is an index of myocardial fiber shortening and thus, it is also influenced by changes in loading conditions
 - Consider BP at time of imaging
- Inaccurate results may be incorrectly accepted
 - How does one know that an abnormal result is real in a patient with an otherwise normal echocardiogram?
- **Clinical limitation:** how do we treat an asymptomatic patient with normal LVEF who has abnormal global or regional strain

Quantitating Ventricular Function: How to use Global Longitudinal Strain?



Predicting Outcome

- Regional strain may help in the detection of regional abnormalities in CAD and selective cardiomyopathies
- Reduction of GLS in cancer patients receiving cardio-toxic agents can predict a drop in EF but the GLS thresholds are still under validation
- GLS provides a **better prediction of CV events and mortality than EF**, in patients with HF, valvular lesions and sepsis.
- Stay tune as new treatment guidelines apply e GLS data to patient management



Thanks